Research
Retatrutide phase 3 data shows sustained metabolic improvements at 68 weeks
Interim results from the TRIUMPH program suggest the triple agonist maintains its lead over dual-incretin therapy on weight and liver-fat endpoints.
Research
Study summaries, mechanism reviews, and scientific analysis — written in plain English and graded against a transparent evidence taxonomy.
BPC-157 mechanisms: what the latest evidence actually supports
Angiogenesis modulation, growth-factor signaling, and the gaps between rodent data and human claims.
ScienceSemaglutide vs. tirzepatide: what head-to-head data shows
SURMOUNT-5 and real-world cohorts consistently favor the dual agonist on weight endpoints — with nuances the headlines skip.
ResearchGHK-Cu research review: skin, hair, and the injectable evidence gap
Strong topical literature, thin injectable data — a compound with a genuinely split evidence base.
ScienceClinical trial tracker: peptide and GLP-1 programs to watch in late 2026
Phase 3 readouts, new obesity candidates, and the muscle-preservation programs entering the clinic.
Clinical TrialsIpamorelin and CJC-1295: what stacked GH-axis research actually measures
The synergy claim has real pharmacology behind it — and important measurement caveats.
ScienceMOTS-c and mitochondrial peptides: an emerging research class
Peptides encoded in mitochondrial DNA are rewriting assumptions about the genome’s smallest products.
ScienceEpitalon and the replication problem in longevity peptides
Decades of source-country research, near-zero independent replication: how to weigh geographically concentrated evidence.
ScienceTesamorelin: the approved GHRH analog most researchers overlook
A full FDA approval, phase 3 visceral-fat data, and lessons for evaluating its gray-market cousins.
ScienceSelank and Semax: evaluating the Russian clinical peptides
Approved in one country, unstudied in most others — a framework for reading asymmetric evidence.
ScienceAOD-9604: when a compound outlives its failed trials
The obesity program failed in 2007. The marketing never stopped. A case study in zombie evidence.
ScienceThe Peptide Institute Weekly
Research. Testing. Regulation. No hype.
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
- New research, summarized in plain English
- Independent lab results as they publish
- Score and ranking movements